The White House said that by the end of next month, the United States will still provide enough vaccines for all Americans, despite the single batch of “medicine” problems, resulting in the loss of 15 million doses of Johnson & Johnson vaccine.
Psaki said on Monday: “We are still expected to vaccinate all adult Americans at the required dose by the end of May.”; “This is not even an FDA-approved facility.”
She went on to say that the United States did not “betting on these doses” and Johnson & Johnson “has assured us that we will receive the 24 million doses they promised in April.”
Under pressure from Kaitlan Collins of CNN, Csaki asked whether the question might exacerbate the national vaccine hesitation.
She said: “This is why the FDA approval process is in place.” “In many ways, this process is working because the FDA did not approve the site. We have taken steps to resolve some issues, and we have also developed a Series contingency plans.”
“When all of us are talking about’Why do we order so many doses, why do we share the dose with every country in the world?” Part of the reason is because we need to plan for what is about to happen. she says.
Psaki added: “We have to plan for a series of emergencies.” “This is one of the many reasons why we need to be able to provide enough vaccines for adult Americans before the end of May.”
Some background: As previously reported by CNN, a source familiar with the Johnson & Johnson vaccine production process told CNN on Saturday that the loss is not a major setback.
Johnson & Johnson has stated that a single batch of “medicine” has not passed the quality control inspection and has been discarded. The company’s vaccine is currently distributed in the United States and is produced in a plant in the Netherlands, but contract manufacturer Emergent BioSolutions produces the vaccine in a plant in Baltimore. The factory was waiting for authorization from the U.S. Food and Drug Administration when reporting the pollution problem.
Once the factory resumes operations, the special vaccine can be produced in these large batches, so making up for this batch of production will not become a major setback. This should be a setback in just a few weeks,” the source told CNN.
Emergent is still producing a vaccine for AstraZeneca, which has not yet been approved In the United States. Like Johnson & Johnson, AstraZeneca’s vaccine also uses viruses to carry genetic material, so-called viral vectors.
Emergent and Johnson & Johnson have said that quality control measures have solved the problem. None of the vaccines produced at the factory were shipped out or put in vials or distributed, and officials emphasized that no one was at risk because of contamination.
People familiar with the matter said that CNN reported that the company has been assisting Johnson & Johnson and AstraZeneca to produce the Covid-19 vaccine for several months.
The source said that in addition to the 15 million doses of vaccine that must be discarded, Emergent has also successfully produced 115 million doses of Johnson & Johnson vaccines, which are in various stages of the supply chain.
The source added that the pharmaceutical industry must discard batches of vaccines “that is not the case,” and the fact that Emergent and Johnson & Johnson detected contamination before shipping any affected doses “shows that the system is effective.”